{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:00:12Z","timestamp":1779145212244,"version":"3.51.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s11912-024-01631-5","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T16:02:04Z","timestamp":1736092924000},"page":"59-67","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["New Developments in VHL-Associated Neuroendocrine Neoplasms"],"prefix":"10.1007","volume":"27","author":[{"given":"Marina","family":"Tsoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Panagaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisavet","family":"Tasouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dionysia","family":"Kolomodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Kaltsas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,5]]},"reference":[{"issue":"3","key":"1631_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/cncr.33978","volume":"128","author":"S Laks","year":"2022","unstructured":"Laks S, van Leeuwaarde R, Patel D, Keutgen XM, Hammel P, Nilubol N, et al. Management recommendations for pancreatic manifestations of Von Hippel-Lindau disease. Cancer. 2022;128(3):435\u201346.","journal-title":"Cancer"},{"key":"1631_CR2","doi-asserted-by":"crossref","unstructured":"Halperin R, Tirosh A. Non-interventional management of advanced pancreatic neuroendocrine neoplasms in patients with Von Hippel-Lindau Disease. Cancers (Basel). 2023;15(6).","DOI":"10.3390\/cancers15061739"},{"key":"1631_CR3","doi-asserted-by":"crossref","unstructured":"Halperin R, Arnon L, Eden-Friedman Y, Tirosh A. Unique characteristics of patients with Von Hippel-Lindau Disease defined by various diagnostic criteria. Cancers (Basel). 2023;15(6).","DOI":"10.3390\/cancers15061657"},{"key":"1631_CR4","unstructured":"van Leeuwaarde RS, Ahmad S, van Nesselrooij B, Zandee W, Giles RH et al. Von Hippel-Lindau Syndrome. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, editors. GeneReviews((R)). Seattle (WA) 1993."},{"issue":"3","key":"1631_CR5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.21037\/jgo.2020.03.09","volume":"11","author":"JL Geurts","year":"2020","unstructured":"Geurts JL. Inherited syndromes involving pancreatic neuroendocrine tumors. J Gastrointest Oncol. 2020;11(3):559\u201366.","journal-title":"J Gastrointest Oncol"},{"issue":"9","key":"1631_CR6","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1002\/ajmg.a.38324","volume":"173","author":"K Launbjerg","year":"2017","unstructured":"Launbjerg K, Bache I, Galanakis M, Bisgaard ML, Binderup MLM. Von Hippel-Lindau development in children and adolescents. Am J Med Genet A. 2017;173(9):2381\u201394.","journal-title":"Am J Med Genet A"},{"issue":"8","key":"1631_CR7","doi-asserted-by":"publisher","first-page":"104538","DOI":"10.1016\/j.ejmg.2022.104538","volume":"65","author":"MBM Louise","year":"2022","unstructured":"Louise MBM, Smerdel M, Borgwadt L, Beck Nielsen SS, Madsen MG, Moller HU, et al. Von Hippel-Lindau disease: updated guideline for diagnosis and surveillance. Eur J Med Genet. 2022;65(8):104538.","journal-title":"Eur J Med Genet"},{"issue":"7 Suppl","key":"1631_CR8","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1002\/cncr.23648","volume":"113","author":"RT Jensen","year":"2008","unstructured":"Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer. 2008;113(7 Suppl):1807\u201343.","journal-title":"Cancer"},{"issue":"18","key":"1631_CR9","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after carcinoid: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063\u201372.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1631_CR10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000441897","volume":"104","author":"I Huguet","year":"2017","unstructured":"Huguet I, Grossman AB, O\u2019Toole D. Changes in the epidemiology of neuroendocrine tumours. Neuroendocrinology. 2017;104(2):105\u201311.","journal-title":"Neuroendocrinology"},{"issue":"10","key":"1631_CR11","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335\u201342.","journal-title":"JAMA Oncol"},{"issue":"7643","key":"1631_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nature21063","volume":"543","author":"A Scarpa","year":"2017","unstructured":"Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543(7643):65\u201371.","journal-title":"Nature"},{"issue":"3","key":"1631_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.4158\/EP.6.3.249","volume":"6","author":"M Ariton","year":"2000","unstructured":"Ariton M, Juan CS, AvRuskin TW. Pheochromocytoma: clinical observations from a Brooklyn tertiary hospital. Endocr Pract. 2000;6(3):249\u201352.","journal-title":"Endocr Pract"},{"issue":"9486","key":"1631_CR14","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(05)67139-5","volume":"366","author":"JW Lenders","year":"2005","unstructured":"Lenders JW, Eisenhofer G, Mannelli M, Pacak K, Phaeochromocytoma. Lancet. 2005;366(9486):665\u201375.","journal-title":"Lancet"},{"issue":"6","key":"1631_CR15","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1056\/NEJMra1806651","volume":"381","author":"HPH Neumann","year":"2019","unstructured":"Neumann HPH, Young WF Jr., Eng C. Pheochromocytoma and Paraganglioma. N Engl J Med. 2019;381(6):552\u201365.","journal-title":"N Engl J Med"},{"issue":"2","key":"1631_CR16","doi-asserted-by":"publisher","first-page":"101346","DOI":"10.1016\/j.beem.2019.101346","volume":"34","author":"E Sbardella","year":"2020","unstructured":"Sbardella E, Grossman AB. Pheochromocytoma: an approach to diagnosis. Best Pract Res Clin Endocrinol Metab. 2020;34(2):101346.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1631_CR17","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3389\/fendo.2018.00515","volume":"9","author":"R Alrezk","year":"2018","unstructured":"Alrezk R, Suarez A, Tena I, Pacak K. Update of Pheochromocytoma syndromes: Genetics, biochemical evaluation, and imaging. Front Endocrinol (Lausanne). 2018;9:515.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"1631_CR18","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1530\/ERC-18-0100","volume":"25","author":"T Krauss","year":"2018","unstructured":"Krauss T, Ferrara AM, Links TP, Wellner U, Bancos I, Kvachenyuk A, et al. Preventive medicine of Von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2018;25(9):783\u201393.","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"1631_CR19","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.surg.2007.09.012","volume":"142","author":"JA Blansfield","year":"2007","unstructured":"Blansfield JA, Choyke L, Morita SY, Choyke PL, Pingpank JF, Alexander HR, et al. Clinical, genetic and radiographic analysis of 108 patients with Von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery. 2007;142(6):814\u20138. discussion 8 e1-2.","journal-title":"Surgery"},{"issue":"3","key":"1631_CR20","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00535-013-0794-1","volume":"49","author":"H Igarashi","year":"2014","unstructured":"Igarashi H, Ito T, Nishimori I, Tamura K, Yamasaki I, Tanaka M, et al. Pancreatic involvement in Japanese patients with Von Hippel-Lindau disease: results of a nationwide survey. J Gastroenterol. 2014;49(3):511\u20136.","journal-title":"J Gastroenterol"},{"issue":"2","key":"1631_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000443171","volume":"103","author":"M Falconi","year":"2016","unstructured":"Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, et al. ENETS Consensus guidelines Update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103(2):153\u201371.","journal-title":"Neuroendocrinology"},{"issue":"1","key":"1631_CR22","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1001\/jamaoncol.2017.3428","volume":"4","author":"A Tirosh","year":"2018","unstructured":"Tirosh A, Sadowski SM, Linehan WM, Libutti SK, Patel D, Nilubol N, et al. Association of VHL genotype with pancreatic neuroendocrine tumor phenotype in patients with Von Hippel-Lindau Disease. JAMA Oncol. 2018;4(1):124\u20136.","journal-title":"JAMA Oncol"},{"issue":"3","key":"1631_CR23","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1159\/000471879","volume":"105","author":"A Sundin","year":"2017","unstructured":"Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, et al. ENETS Consensus guidelines for the standards of Care in Neuroendocrine tumors: Radiological, Nuclear Medicine & Hybrid Imaging. Neuroendocrinology. 2017;105(3):212\u201344.","journal-title":"Neuroendocrinology"},{"issue":"2","key":"1631_CR24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jamcollsurg.2013.10.025","volume":"218","author":"AB Weisbrod","year":"2014","unstructured":"Weisbrod AB, Kitano M, Thomas F, Williams D, Gulati N, Gesuwan K, et al. Assessment of tumor growth in pancreatic neuroendocrine tumors in Von Hippel Lindau syndrome. J Am Coll Surg. 2014;218(2):163\u20139.","journal-title":"J Am Coll Surg"},{"key":"1631_CR25","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ejrad.2018.11.023","volume":"112","author":"J Shell","year":"2019","unstructured":"Shell J, Tirosh A, Millo C, Sadowski SM, Assadipour Y, Green P, et al. The utility of (68)Gallium-DOTATATE PET\/CT in the detection of Von Hippel-Lindau disease associated tumors. Eur J Radiol. 2019;112:130\u20135.","journal-title":"Eur J Radiol"},{"issue":"3","key":"1631_CR26","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1148\/radiol.2253011297","volume":"225","author":"HB Marcos","year":"2002","unstructured":"Marcos HB, Libutti SK, Alexander HR, Lubensky IA, Bartlett DL, Walther MM, et al. Neuroendocrine tumors of the pancreas in Von Hippel-Lindau disease: spectrum of appearances at CT and MR imaging with histopathologic comparison. Radiology. 2002;225(3):751\u20138.","journal-title":"Radiology"},{"issue":"5","key":"1631_CR27","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1530\/EJE-15-1012","volume":"174","author":"SJ van Asselt","year":"2016","unstructured":"van Asselt SJ, Brouwers AH, van Dullemen HM, van der Jagt EJ, Bongaerts AH, Koopmans KP, et al. Potential value of EUS in pancreatic surveillance of VHL patients. Eur J Endocrinol. 2016;174(5):611\u201320.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1631_CR28","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.jamcollsurg.2014.01.004","volume":"218","author":"SM Sadowski","year":"2014","unstructured":"Sadowski SM, Weisbrod AB, Ellis R, Patel D, Alimchandani M, Quezado M, et al. Prospective evaluation of the clinical utility of 18-fluorodeoxyglucose PET CT scanning in patients with Von hippel-lindau-associated pancreatic lesions. J Am Coll Surg. 2014;218(5):997\u20131003.","journal-title":"J Am Coll Surg"},{"key":"1631_CR29","doi-asserted-by":"crossref","unstructured":"Tsoli M, Daskalakis K, Kassi E, Kaltsas G, Tsolakis AV. A critical Appraisal of contemporary and novel biomarkers in Pheochromocytomas and Adrenocortical tumors. Biology (Basel). 2021;10(7).","DOI":"10.3390\/biology10070580"},{"issue":"5","key":"1631_CR30","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1530\/EJE-16-1079","volume":"176","author":"A Tirosh","year":"2017","unstructured":"Tirosh A, Papadakis GZ, Millo C, Sadowski SM, Herscovitch P, Pacak K, et al. Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total (68)Ga-DOTATATE-Avid tumor volume measurements. Eur J Endocrinol. 2017;176(5):575\u201382.","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"1631_CR31","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1093\/annonc\/mdr011","volume":"22","author":"E Jonasch","year":"2011","unstructured":"Jonasch E, McCutcheon IE, Waguespack SG, Wen S, Davis DW, Smith LA, et al. Pilot trial of sunitinib therapy in patients with Von Hippel-Lindau disease. Ann Oncol. 2011;22(12):2661\u20136.","journal-title":"Ann Oncol"},{"issue":"10","key":"1631_CR32","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S1470-2045(18)30487-X","volume":"19","author":"E Jonasch","year":"2018","unstructured":"Jonasch E, McCutcheon IE, Gombos DS, Ahrar K, Perrier ND, Liu D, et al. Pazopanib in patients with Von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. Lancet Oncol. 2018;19(10):1351\u20139.","journal-title":"Lancet Oncol"},{"issue":"22","key":"1631_CR33","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","volume":"385","author":"E Jonasch","year":"2021","unstructured":"Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, et al. Belzutifan for Renal Cell Carcinoma in Von Hippel-Lindau Disease. N Engl J Med. 2021;385(22):2036\u201346.","journal-title":"N Engl J Med"},{"issue":"19","key":"1631_CR34","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1002\/cncr.34896","volume":"129","author":"AB Daniels","year":"2023","unstructured":"Daniels AB, Tirosh A, Huntoon K, Mehta GU, Spiess PE, Friedman DL, et al. Guidelines for surveillance of patients with Von Hippel-Lindau disease: Consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance. Cancer. 2023;129(19):2927\u201340.","journal-title":"Cancer"},{"issue":"2","key":"1631_CR35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1210\/endrev\/bnab019","volume":"43","author":"S Nolting","year":"2022","unstructured":"Nolting S, Bechmann N, Taieb D, Beuschlein F, Fassnacht M, Kroiss M, et al. Personalized Management of Pheochromocytoma and Paraganglioma. Endocr Rev. 2022;43(2):199\u2013239.","journal-title":"Endocr Rev"},{"issue":"1","key":"1631_CR36","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/humu.1380050109","volume":"5","author":"F Chen","year":"1995","unstructured":"Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, et al. Germline mutations in the Von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat. 1995;5(1):66\u201375.","journal-title":"Hum Mutat"},{"issue":"7","key":"1631_CR37","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1093\/neuonc\/nov313","volume":"18","author":"A Feletti","year":"2016","unstructured":"Feletti A, Anglani M, Scarpa B, Schiavi F, Boaretto F, Zovato S, et al. Von Hippel-Lindau disease: an evaluation of natural history and functional disability. Neuro Oncol. 2016;18(7):1011\u201320.","journal-title":"Neuro Oncol"},{"issue":"4","key":"1631_CR38","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1136\/jmg.33.4.328","volume":"33","author":"ER Maher","year":"1996","unstructured":"Maher ER, Webster AR, Richards FM, Green JS, Crossey PA, Payne SJ, et al. Phenotypic expression in Von Hippel-Lindau disease: correlations with germline VHL gene mutations. J Med Genet. 1996;33(4):328\u201332.","journal-title":"J Med Genet"},{"issue":"1","key":"1631_CR39","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nrc3844","volume":"15","author":"L Gossage","year":"2015","unstructured":"Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer. 2015;15(1):55\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"1631_CR40","doi-asserted-by":"publisher","first-page":"R293","DOI":"10.1530\/EC-21-0294","volume":"10","author":"J Castro-Teles","year":"2021","unstructured":"Castro-Teles J, Sousa-Pinto B, Rebelo S, Pignatelli D. Pheochromocytomas and paragangliomas in Von Hippel-Lindau disease: not a needle in a haystack. Endocr Connect. 2021;10(11):R293\u2013304.","journal-title":"Endocr Connect"},{"issue":"11","key":"1631_CR41","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.1210\/jc.2009-1479","volume":"94","author":"J Gaal","year":"2009","unstructured":"Gaal J, van Nederveen FH, Erlic Z, Korpershoek E, Oldenburg R, Boedeker CC, et al. Parasympathetic paragangliomas are part of the Von Hippel-Lindau syndrome. J Clin Endocrinol Metab. 2009;94(11):4367\u201371.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1631_CR42","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1158\/1078-0432.CCR-17-0547","volume":"23","author":"SP Rednam","year":"2017","unstructured":"Rednam SP, Erez A, Druker H, Janeway KA, Kamihara J, Kohlmann WK, et al. Von Hippel-Lindau and Hereditary Pheochromocytoma\/Paraganglioma Syndromes: clinical features, Genetics, and Surveillance recommendations in Childhood. Clin Cancer Res. 2017;23(12):e68\u201375.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1631_CR43","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s00268-019-05299-y","volume":"44","author":"SR Li","year":"2020","unstructured":"Li SR, Nicholson KJ, McCoy KL, Carty SE, Yip L. Clinical and biochemical features of pheochromocytoma characteristic of Von Hippel-Lindau Syndrome. World J Surg. 2020;44(2):570\u20137.","journal-title":"World J Surg"},{"issue":"6","key":"1631_CR44","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/ejhg.2010.175","volume":"19","author":"ER Maher","year":"2011","unstructured":"Maher ER, Neumann HP, Richard S. Von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet. 2011;19(6):617\u201323.","journal-title":"Eur J Hum Genet"},{"issue":"6","key":"1631_CR45","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1210\/jc.2014-1498","volume":"99","author":"JW Lenders","year":"2014","unstructured":"Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915\u201342.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1631_CR46","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/bjs.6937","volume":"97","author":"M Schiesser","year":"2010","unstructured":"Schiesser M, Veit-Haibach P, Muller MK, Weber M, Bauerfeind P, Hany T, et al. Value of combined 6-[18F]fluorodihydroxyphenylalanine PET\/CT for imaging of neuroendocrine tumours. Br J Surg. 2010;97(5):691\u20137.","journal-title":"Br J Surg"},{"issue":"10","key":"1631_CR47","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","volume":"46","author":"D Taieb","year":"2019","unstructured":"Taieb D, Hicks RJ, Hindie E, Guillet BA, Avram A, Ghedini P, et al. European Association of Nuclear Medicine Practice Guideline\/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2019;46(10):2112\u201337.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1631_CR48","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/S1470-2045(14)70154-8","volume":"15","author":"F Castinetti","year":"2014","unstructured":"Castinetti F, Qi XP, Walz MK, Maia AL, Sanso G, Peczkowska M, et al. Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. Lancet Oncol. 2014;15(6):648\u201355.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1631_CR49","doi-asserted-by":"publisher","first-page":"e198898","DOI":"10.1001\/jamanetworkopen.2019.8898","volume":"2","author":"HPH Neumann","year":"2019","unstructured":"Neumann HPH, Tsoy U, Bancos I, Amodru V, Walz MK, Tirosh A, et al. Comparison of pheochromocytoma-specific morbidity and mortality among adults with bilateral Pheochromocytomas undergoing total adrenalectomy vs Cortical-Sparing Adrenalectomy. JAMA Netw Open. 2019;2(8):e198898.","journal-title":"JAMA Netw Open"},{"key":"1631_CR50","doi-asserted-by":"crossref","unstructured":"Nolting S, Ullrich M, Pietzsch J, Ziegler CG, Eisenhofer G, Grossman A et al. Current management of Pheochromocytoma\/Paraganglioma: a guide for the practicing clinician in the era of Precision Medicine. Cancers (Basel). 2019;11(10).","DOI":"10.3390\/cancers11101505"},{"issue":"1","key":"1631_CR51","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/SLA.0000000000002195","volume":"268","author":"A Roman-Gonzalez","year":"2018","unstructured":"Roman-Gonzalez A, Zhou S, Ayala-Ramirez M, Shen C, Waguespack SG, Habra MA, et al. Impact of Surgical Resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma. Ann Surg. 2018;268(1):172\u20138.","journal-title":"Ann Surg"},{"issue":"6","key":"1631_CR52","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1245\/s10434-016-5739-5","volume":"24","author":"V Strajina","year":"2017","unstructured":"Strajina V, Dy BM, Farley DR, Richards ML, McKenzie TJ, Bible KC, et al. Surgical Treatment of Malignant Pheochromocytoma and Paraganglioma: Retrospective Case Series. Ann Surg Oncol. 2017;24(6):1546\u201350.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"1631_CR53","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2967\/jnumed.118.217463","volume":"60","author":"DA Pryma","year":"2019","unstructured":"Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, Solnes L, et al. Efficacy and safety of high-specific-activity (131)I-MIBG therapy in patients with Advanced Pheochromocytoma or Paraganglioma. J Nucl Med. 2019;60(5):623\u201330.","journal-title":"J Nucl Med"},{"issue":"2","key":"1631_CR54","doi-asserted-by":"publisher","first-page":"101354","DOI":"10.1016\/j.beem.2019.101354","volume":"34","author":"S Jasim","year":"2020","unstructured":"Jasim S, Jimenez C. Metastatic pheochromocytoma and paraganglioma: management of endocrine manifestations, surgery and ablative procedures, and systemic therapies. Best Pract Res Clin Endocrinol Metab. 2020;34(2):101354.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"11","key":"1631_CR55","doi-asserted-by":"publisher","first-page":"R627","DOI":"10.1530\/ERC-19-0165","volume":"26","author":"D Taieb","year":"2019","unstructured":"Taieb D, Jha A, Treglia G, Pacak K. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Endocr Relat Cancer. 2019;26(11):R627\u201352.","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"1631_CR56","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","volume":"31","author":"M Fassnacht","year":"2020","unstructured":"Fassnacht M, Assie G, Baudin E, Eisenhofer G, de la Fouchardiere C, Haak HR, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1476\u201390.","journal-title":"Ann Oncol"},{"issue":"10431","key":"1631_CR57","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S0140-6736(23)02554-0","volume":"403","author":"E Baudin","year":"2024","unstructured":"Baudin E, Goichot B, Berruti A, Hadoux J, Moalla S, Laboureau S, et al. Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial. Lancet. 2024;403(10431):1061\u201370.","journal-title":"Lancet"},{"issue":"9","key":"1631_CR58","doi-asserted-by":"publisher","first-page":"e7094","DOI":"10.1371\/journal.pone.0007094","volume":"4","author":"J Favier","year":"2009","unstructured":"Favier J, Briere JJ, Burnichon N, Riviere J, Vescovo L, Benit P, et al. The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS ONE. 2009;4(9):e7094.","journal-title":"PLoS ONE"},{"issue":"13","key":"1631_CR59","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1016\/j.celrep.2020.03.022","volume":"30","author":"A Morin","year":"2020","unstructured":"Morin A, Goncalves J, Moog S, Castro-Vega LJ, Job S, Buffet A, et al. TET-Mediated hypermethylation primes SDH-Deficient cells for HIF2alpha-Driven mesenchymal transition. Cell Rep. 2020;30(13):4551\u201366. e7.","journal-title":"Cell Rep"},{"issue":"16","key":"1631_CR60","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1056\/NEJMc2409427","volume":"391","author":"H Alkaissi","year":"2024","unstructured":"Alkaissi H, Nazari MA, Hadrava Vanova K, Uher O, Gordon CM, Talvacchio S, et al. Rapid Cardiovascular Response to Belzutifan in HIF2A-Mediated paraganglioma. N Engl J Med. 2024;391(16):1552\u20135.","journal-title":"N Engl J Med"},{"issue":"12","key":"1631_CR61","doi-asserted-by":"publisher","first-page":"4498","DOI":"10.1210\/jc.2015-3045","volume":"100","author":"RD Aufforth","year":"2015","unstructured":"Aufforth RD, Ramakant P, Sadowski SM, Mehta A, Trebska-McGowan K, Nilubol N, et al. Pheochromocytoma screening initiation and frequency in Von Hippel-Lindau Syndrome. J Clin Endocrinol Metab. 2015;100(12):4498\u2013504.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-024-01631-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-024-01631-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-024-01631-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T06:46:05Z","timestamp":1737787565000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-024-01631-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1631"],"URL":"https:\/\/doi.org\/10.1007\/s11912-024-01631-5","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"22 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}